688117 圣诺生物
交易中 07-22 13:43:59
资讯
新帖
简况
7月21日圣诺生物发布公告,股东增持200.55万股
证券之星 · 07-21 19:01
7月21日圣诺生物发布公告,股东增持200.55万股
每周股票复盘:圣诺生物(688117)上半年净利预增43.23%至64.79%
证券之星 · 07-19
每周股票复盘:圣诺生物(688117)上半年净利预增43.23%至64.79%
圣诺生物(688117)披露2026年限制性股票激励计划首次授予激励对象名单审核及公示情况说明,7月17日股价下跌14.29%
证券之星 · 07-17
圣诺生物(688117)披露2026年限制性股票激励计划首次授予激励对象名单审核及公示情况说明,7月17日股价下跌14.29%
股市必读:圣诺生物(688117)新发布《关于2025年年度报告的信息披露监管问询函的回复公告》
证券之星 · 07-13
股市必读:圣诺生物(688117)新发布《关于2025年年度报告的信息披露监管问询函的回复公告》
今晚,七家公司发布利好!
证券之星 · 07-12
今晚,七家公司发布利好!
圣诺生物:预计2026年1-6月归属净利润盈利1.27亿元至1.47亿元
证券之星 · 07-12
圣诺生物:预计2026年1-6月归属净利润盈利1.27亿元至1.47亿元
圣诺生物最新公告:预计2026年半年度净利润同比增长43.23%-64.79%
证券之星 · 07-12
圣诺生物最新公告:预计2026年半年度净利润同比增长43.23%-64.79%
圣诺生物:预计2026年上半年净利同比增43.23%-64.79%
格隆汇 · 07-12
圣诺生物:预计2026年上半年净利同比增43.23%-64.79%
圣诺生物(688117)披露2025年年度报告监管问询函回复公告,7月10日股价上涨2.74%
证券之星 · 07-10
圣诺生物(688117)披露2025年年度报告监管问询函回复公告,7月10日股价上涨2.74%
圣诺生物(688117.SH)拟推2026年限制性股票激励计划
智通财经 · 07-07
圣诺生物(688117.SH)拟推2026年限制性股票激励计划
每周股票复盘:圣诺生物(688117)控股股东拟增持4000万至5000万元
证券之星 · 07-05
每周股票复盘:圣诺生物(688117)控股股东拟增持4000万至5000万元
圣诺生物(688117)披露控股股东增持公司股份计划公告,7月3日股价上涨3.01%
证券之星 · 07-03
圣诺生物(688117)披露控股股东增持公司股份计划公告,7月3日股价上涨3.01%
圣诺生物(688117.SH)控股股东拟4000万元至5000万元增持公司股份
智通财经 · 07-03
圣诺生物(688117.SH)控股股东拟4000万元至5000万元增持公司股份
每周股票复盘:圣诺生物(688117)培来加南原料药获上市批准
证券之星 · 06-28
每周股票复盘:圣诺生物(688117)培来加南原料药获上市批准
圣诺生物(688117.SH):培来加南原料药获得上市申请批准通知书
智通财经 · 06-25
圣诺生物(688117.SH):培来加南原料药获得上市申请批准通知书
每周股票复盘:圣诺生物(688117)缩宫素原料药获上市批准
证券之星 · 06-20
每周股票复盘:圣诺生物(688117)缩宫素原料药获上市批准
圣诺生物(688117.SH):缩宫素原料药获得上市申请批准通知书
智通财经 · 06-18
圣诺生物(688117.SH):缩宫素原料药获得上市申请批准通知书
圣诺生物(688117.SH)副总经理拟800万元至1000万元增持公司股份
智通财经 · 06-08
圣诺生物(688117.SH)副总经理拟800万元至1000万元增持公司股份
每周股票复盘:DR圣诺生(688117)拟每股派现0.32元转增0.4股
证券之星 · 06-07
每周股票复盘:DR圣诺生(688117)拟每股派现0.32元转增0.4股
圣诺生物:相关专利到期并不等同于司美格鲁肽原料药可在全球范围内销售而不受限制
证券之星 · 06-05
圣诺生物:相关专利到期并不等同于司美格鲁肽原料药可在全球范围内销售而不受限制
暂无数据
公司概况
公司名称:
成都圣诺生物科技股份有限公司
所属行业:
医药制造业
上市日期:
2021-06-03
主营业务:
成都圣诺生物科技股份有限公司的主营业务是多肽原料药和制剂产品的研发、生产与销售,同时提供多肽创新药药学研究服务、多肽类产品定制生产服务以及左西孟旦制剂代加工和左西孟旦原料药生产与出口。公司的主要产品是醋酸奥曲肽注射液、注射用生长抑素、卡贝缩宫素注射液、醋酸阿托西班注射液、依替巴肽注射液、注射用胸腺法新、注射用胸腺五肽、注射用恩夫韦肽、艾替班特注射液、泊沙康唑注射液、醋酸加尼瑞克注射液、艾塞那肽注射液。
发行价格:
17.90
{"stockData":{"symbol":"688117","market":"SH","secType":"STK","nameCN":"圣诺生物","latestPrice":24.42,"timestamp":1784699039000,"preClose":24.65,"halted":0,"volume":7635168,"delay":0,"changeRate":-0.0093,"floatShares":220000000,"shares":220000000,"eps":0.8041,"marketStatus":"交易中","change":-0.23,"latestTime":"07-22 13:43:59","open":24.31,"high":25.75,"low":24.1,"amount":190000000,"amplitude":0.0669,"askPrice":24.44,"askSize":4,"bidPrice":24.43,"bidSize":9,"shortable":0,"etf":0,"ttmEps":0.8041,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1784703600000},"marketStatusCode":2,"adr":0,"adjPreClose":24.65,"symbolType":"stock_kcb","openAndCloseTimeList":[[1784683800000,1784691000000],[1784696400000,1784703600000]],"highLimit":27.12,"lowLimit":22.19,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":220340369,"isCdr":false,"pbRate":4.83,"roa":"--","peRate":30.369357,"roe":"6.08%","epsLYR":1,"committee":0.469136,"marketValue":5381000000,"turnoverRate":0.0347,"status":1,"floatMarketCap":5381000000},"requestUrl":"/m/hq/s/688117/tweets","defaultTab":"tweets","newsList":[{"id":"2653271997","title":"7月21日圣诺生物发布公告,股东增持200.55万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653271997","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653271997?lang=zh_cn&edition=full","pubTime":"2026-07-21 19:01","pubTimestamp":1784631676,"startTime":"0","endTime":"0","summary":"证券之星消息,7月21日圣诺生物发布公告《圣诺生物:关于控股股东增持股份结果暨权益变动触及1%刻度的公告》,其股东四川赛诺投资有限公司于2026年7月17日至2026年7月21日间合计增持200.55万股,占公司目前总股本的0.9102%,变动期间该股股价下跌15.15%,截止7月21日收盘报24.65元。股东增减持详情见下表:根据圣诺生物2026年一季报公布的十大股东详情如下:本文数据来源于圣诺生物公告,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100037880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652823749","title":"每周股票复盘:圣诺生物(688117)上半年净利预增43.23%至64.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652823749","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652823749?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:35","pubTimestamp":1784396110,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘,圣诺生物报收于24.9元,较上周的29.21元下跌14.76%。本周关注点公司公告汇总:预计2026年上半年净利润同比增长43.23%至64.79%公司公告汇总:拟授予469.00万股限制性股票用于股权激励公司公告汇总:2026年限制性股票激励对象名单公示无异议公司公告汇总成都圣诺生物科技股份有限公司预计2026年半年度实现归属于母公司所有者的净利润12,741.40万元至14,659.46万元,同比增长43.23%至64.79%;扣除非经常性损益后的净利润为12,595.48万元至14,404.47万元,同比增长44.77%至60.99%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652328604","title":"圣诺生物(688117)披露2026年限制性股票激励计划首次授予激励对象名单审核及公示情况说明,7月17日股价下跌14.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652328604","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652328604?lang=zh_cn&edition=full","pubTime":"2026-07-17 22:10","pubTimestamp":1784297433,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘,圣诺生物报收于24.9元,较前一交易日下跌14.29%,最新总市值为54.86亿元。近日,成都圣诺生物科技股份有限公司披露《董事会薪酬与考核委员会关于公司2026年限制性股票激励计划首次授予激励对象名单的审核意见及公示情况说明》。公告显示,公司于2026年7月8日至7月17日在内部公示激励对象名单,公示期间未收到异议。董事会薪酬与考核委员会认为激励对象主体资格合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700044615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651651991","title":"股市必读:圣诺生物(688117)新发布《关于2025年年度报告的信息披露监管问询函的回复公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2651651991","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651651991?lang=zh_cn&edition=full","pubTime":"2026-07-13 01:07","pubTimestamp":1783876028,"startTime":"0","endTime":"0","summary":"关于2025年年度报告的信息披露监管问询函的回复公告2025年营收7.41亿元,同比增长62.57%,主要因GLP-1原料药境外销售增加;原料药业务中司美格鲁肽、替尔泊肽销售大幅增长;制剂业务受集采影响价格下滑;前五名客户占比65.41%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300000578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650163295","title":"今晚,七家公司发布利好!","url":"https://stock-news.laohu8.com/highlight/detail?id=2650163295","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650163295?lang=zh_cn&edition=full","pubTime":"2026-07-12 20:31","pubTimestamp":1783859460,"startTime":"0","endTime":"0","summary":"业绩变动主要系报告期内公司产品销售毛利率得到改善,从而利润增加。4,亚联机械:2026年半年度净利润同比增长60.06%亚联机械公告称,公司发布2026年半年度业绩快报,实现营业收入5.15亿元,同比增长36.93%;归属于上市公司股东的净利润1.57亿元,同比增长60.06%。业绩增长主要系2026年上半年高单价生产线项目验收较多,且整体毛利率水平较高。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-12/doc-inihqett7718793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0059","BK0251","BK0028","BK0014","BK0005","603819","BK0155","BK0188","BK0000","001313","688117","600884","002866","BK0214","BK0012","BK0238","BK0037","BK0224","600118","BK0239","BK0024","BK0010","BK0051","001395","BK0183"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2650168766","title":"圣诺生物:预计2026年1-6月归属净利润盈利1.27亿元至1.47亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2650168766","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650168766?lang=zh_cn&edition=full","pubTime":"2026-07-12 18:00","pubTimestamp":1783850441,"startTime":"0","endTime":"0","summary":"证券之星消息,圣诺生物发布业绩预告,预计2026年1-6月归属净利润盈利1.27亿元至1.47亿元。圣诺生物2026年一季报显示,一季度公司主营收入2.44亿元,同比上升32.52%;归母净利润6636.22万元,同比上升40.84%;扣非净利润6587.3万元,同比上升37.4%;负债率44.0%,投资收益34.14万元,财务费用438.3万元,毛利率59.87%。本文数据来源于《圣诺生物:2026年半年度业绩预告的自愿性披露公告》,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200009723.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650168634","title":"圣诺生物最新公告:预计2026年半年度净利润同比增长43.23%-64.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650168634","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650168634?lang=zh_cn&edition=full","pubTime":"2026-07-12 16:19","pubTimestamp":1783844386,"startTime":"0","endTime":"0","summary":"圣诺生物(688117.SH)公告称,预计2026年半年度归属于母公司所有者的净利润为1.27亿元-1.47亿元,同比增长43.23%-64.79%。业绩变动主要系公司多肽原料药业务持续增长,新建产能逐步释放,规模化生产效应与工艺优化提升整体盈利能力。注:公司Q2净利润预计0.61亿-0.8亿,Q1净利润0.66亿,据此计算,Q2净利润预计环比变动-8%-20%。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200005276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650168506","title":"圣诺生物:预计2026年上半年净利同比增43.23%-64.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650168506","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650168506?lang=zh_cn&edition=full","pubTime":"2026-07-12 16:19","pubTimestamp":1783844372,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650135108","title":"圣诺生物(688117)披露2025年年度报告监管问询函回复公告,7月10日股价上涨2.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650135108","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650135108?lang=zh_cn&edition=full","pubTime":"2026-07-10 22:16","pubTimestamp":1783692983,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘,圣诺生物报收于29.21元,较前一交易日上涨2.74%,最新总市值为64.36亿元。该股当日开盘28.2元,最高30.3元,最低27.78元,成交额达3.33亿元,换手率为5.12%。近日,圣诺生物发布《关于2025年年度报告的信息披露监管问询函的回复公告》。公告显示,公司就2025年年度报告收到上交所问询函,针对营业收入、客户集中度、应收账款、存货、产能建设、偿债能力等问题逐一回复。公司2025年营收7.41亿元,同比增长62.57%,主要因GLP-1原料药境外销售增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000044373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649813519","title":"圣诺生物(688117.SH)拟推2026年限制性股票激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2649813519","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649813519?lang=zh_cn&edition=full","pubTime":"2026-07-07 18:33","pubTimestamp":1783420402,"startTime":"0","endTime":"0","summary":"智通财经APP讯,圣诺生物(688117.SH)披露2026年限制性股票激励计划(草案),拟授予激励对象的限制性股票数量为469万股,约占激励计划草案公布日公司股本总额的2.13%。其中,首次授予限制性股票449万股,首次授予激励对象共计113人,授予价格为14.88元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649923476","title":"每周股票复盘:圣诺生物(688117)控股股东拟增持4000万至5000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649923476","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649923476?lang=zh_cn&edition=full","pubTime":"2026-07-05 03:29","pubTimestamp":1783193350,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘,圣诺生物报收于30.08元,较上周的23.59元上涨27.51%。本周,圣诺生物7月3日盘中最高价报30.55元。圣诺生物当前最新总市值66.28亿元,在化学制药板块市值排名77/149,在两市A股市值排名2637/5203。公司公告汇总成都圣诺生物科技股份有限公司控股股东四川赛诺投资有限公司计划自公告披露之日起12个月内,通过集中竞价方式增持公司A股股份,增持金额不低于4,000万元且不超过5,000万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500001141.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648610686","title":"圣诺生物(688117)披露控股股东增持公司股份计划公告,7月3日股价上涨3.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648610686","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648610686?lang=zh_cn&edition=full","pubTime":"2026-07-03 22:42","pubTimestamp":1783089741,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘,圣诺生物报收于30.08元,较前一交易日上涨3.01%,最新总市值为66.28亿元。近日,圣诺生物披露《关于控股股东增持公司股份计划的公告》。公告显示,公司控股股东四川赛诺投资有限公司计划自公告披露之日起12个月内,通过集中竞价方式增持公司A股股份,增持金额不低于4,000万元且不超过5,000万元。本次增持不设价格区间,增持期间内不减持所持股份,且增持比例合计不超过公司总股本的2%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300046001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648668846","title":"圣诺生物(688117.SH)控股股东拟4000万元至5000万元增持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2648668846","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648668846?lang=zh_cn&edition=full","pubTime":"2026-07-03 18:06","pubTimestamp":1783073177,"startTime":"0","endTime":"0","summary":"智通财经APP讯,圣诺生物(688117.SH)发布公告,公司控股股东四川赛诺投资有限公司拟自增持计划公告披露之日起12个月内,通过上海证券交易所系统允许的方式(集中竞价)增持公司股份,计划增持金额不低于4000万元且不超过5000万元,资金来源为自有资金和自筹资金(包括股票增持专项贷款)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462986.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"圣诺生物(688117.SH)控股股东拟4000万元至5000万元增持公司股份","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646158273","title":"每周股票复盘:圣诺生物(688117)培来加南原料药获上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2646158273","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646158273?lang=zh_cn&edition=full","pubTime":"2026-06-28 03:00","pubTimestamp":1782586837,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘,圣诺生物报收于23.59元,较上周的23.72元下跌0.55%。本周,圣诺生物6月24日盘中最高价报25.85元。本周关注点公司公告汇总:培来加南原料药获国家药监局上市申请批准。公司公告汇总成都圣诺生物科技股份有限公司全资子公司成都圣诺生物制药有限公司近日收到国家药品监督管理局签发的培来加南原料药《化学原料药上市申请批准通知书》,批准该原料药上市申请。该原料药适用于治疗由特定细菌导致的烧烫伤继发创面感染。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800000842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646878065","title":"圣诺生物(688117.SH):培来加南原料药获得上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2646878065","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646878065?lang=zh_cn&edition=full","pubTime":"2026-06-25 16:30","pubTimestamp":1782376203,"startTime":"0","endTime":"0","summary":"智通财经APP讯,圣诺生物(688117.SH)发布公告,公司全资子公司成都圣诺生物制药有限公司于近日收到国家药品监督管理局签发的关于培来加南原料药的《化学原料药上市申请批准通知书》。培来加南喷雾剂为局部外用抗细菌药物,是多肽类抗感染新药,适用于治疗由表皮葡萄球菌、溶血葡萄球菌、鲍曼不动杆菌导致的Ⅰ度或浅Ⅱ度烧烫伤继发创面感染。该药品上市为患者提供了新的治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644875066","title":"每周股票复盘:圣诺生物(688117)缩宫素原料药获上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2644875066","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644875066?lang=zh_cn&edition=full","pubTime":"2026-06-20 03:31","pubTimestamp":1781897469,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘,圣诺生物报收于23.72元,较上周的23.57元上涨0.64%。本周,圣诺生物6月15日盘中最高价报25.25元。6月17日盘中最低价报22.7元。圣诺生物当前最新总市值52.26亿元,在化学制药板块市值排名85/150,在两市A股市值排名3164/5206。缩宫素为多肽子宫收缩药,用于引产、催产、产后及流产后子宫出血。该批准有利于丰富公司产品线,拓展品种销售,提升市场竞争力。具体销售情况受政策和市场环境影响存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000002071.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644709809","title":"圣诺生物(688117.SH):缩宫素原料药获得上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2644709809","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644709809?lang=zh_cn&edition=full","pubTime":"2026-06-18 17:00","pubTimestamp":1781773234,"startTime":"0","endTime":"0","summary":"智通财经APP讯,圣诺生物(688117.SH)发布公告,公司全资子公司成都圣诺生物制药有限公司于近日收到国家药品监督管理局签发的关于缩宫素原料药的《化学原料药上市申请批准通知书》。本次缩宫素原料药获得上市申请批准通知书,表明该原料药已符合国家药品注册的有关规定要求,将进一步丰富公司的原料药产品线,有利于公司拓展该品种的销售,同时也为公司后续药品研究积累了丰富的经验,提升公司市场竞争力,对公司经营发展具有一定的积极作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456162.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","IPOS","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641848801","title":"圣诺生物(688117.SH)副总经理拟800万元至1000万元增持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2641848801","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641848801?lang=zh_cn&edition=full","pubTime":"2026-06-08 17:50","pubTimestamp":1780912219,"startTime":"0","endTime":"0","summary":"智通财经APP讯,圣诺生物(688117.SH)发布公告,公司副总经理、董事会秘书饶进拟自增持计划公告披露之日起6个月内,通过上海证券交易所系统允许的方式(包括但不限于集中竞价和大宗交易等)增持股份,计划增持金额不低于800万元且不超过1000万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641127962","title":"每周股票复盘:DR圣诺生(688117)拟每股派现0.32元转增0.4股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641127962","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641127962?lang=zh_cn&edition=full","pubTime":"2026-06-07 02:35","pubTimestamp":1780770912,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘,DR圣诺生报收于23.04元,较上周的33.73元下跌31.69%。本周,DR圣诺生6月1日盘中最高价报35.2元。DR圣诺生当前最新总市值50.77亿元,在化学制药板块市值排名89/150,在两市A股市值排名3302/5206。本次权益分派以公司总股本157,385,978股为基数,向全体股东每股派发现金红利0.32元(含税),每股转增0.4股,共计派发现金红利50,363,512.96元,转增62,954,391股,分配后总股本增至220,340,369股。本次资本公积金转增股本来源于股票溢价发行收入,不扣税。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000791.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641114899","title":"圣诺生物:相关专利到期并不等同于司美格鲁肽原料药可在全球范围内销售而不受限制","url":"https://stock-news.laohu8.com/highlight/detail?id=2641114899","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641114899?lang=zh_cn&edition=full","pubTime":"2026-06-05 18:06","pubTimestamp":1780653991,"startTime":"0","endTime":"0","summary":"证券之星消息,DR圣诺生(688117)06月05日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘你好,司美格鲁肽原料专利3月20号到期是不是意味着公司的司美格鲁肽原料可以全球开卖了,DR圣诺生回复:尊敬的投资者您好,相关专利到期并不等同于司美格鲁肽原料药可在全球范围内销售而不受限制,各国家和地区的专利状态、药品注册备案、质量体系要求及商业化进度等均存在差异。公司将持续关注GLP-1类多肽原料药的市场机会,积极拓展国际销售渠道,同时严格遵守相关知识产权和药品监管相关法律法规。感谢您的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500031382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784699044640,"stockEarnings":[{"period":"1week","weight":-0.1417},{"period":"1month","weight":0.0392},{"period":"3month","weight":-0.0831},{"period":"6month","weight":-0.1422},{"period":"1year","weight":-0.1793},{"period":"ytd","weight":-0.0777}],"compareEarnings":[{"period":"1week","weight":-0.0259},{"period":"1month","weight":-0.0553},{"period":"3month","weight":-0.0589},{"period":"6month","weight":-0.0626},{"period":"1year","weight":0.0856},{"period":"ytd","weight":-0.0263}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"成都圣诺生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10014人(较上一季度增加18.89%)","perCapita":"22003股","listingDate":"2021-06-03","address":"四川省成都市大邑县大安路98号","registeredCapital":"22034万元","survey":" 成都圣诺生物科技股份有限公司的主营业务是多肽原料药和制剂产品的研发、生产与销售,同时提供多肽创新药药学研究服务、多肽类产品定制生产服务以及左西孟旦制剂代加工和左西孟旦原料药生产与出口。公司的主要产品是醋酸奥曲肽注射液、注射用生长抑素、卡贝缩宫素注射液、醋酸阿托西班注射液、依替巴肽注射液、注射用胸腺法新、注射用胸腺五肽、注射用恩夫韦肽、艾替班特注射液、泊沙康唑注射液、醋酸加尼瑞克注射液、艾塞那肽注射液。","listedPrice":17.9},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"圣诺生物(688117)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供圣诺生物(688117)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"圣诺生物,688117,圣诺生物股票,圣诺生物股票老虎,圣诺生物股票老虎国际,圣诺生物行情,圣诺生物股票行情,圣诺生物股价,圣诺生物股市,圣诺生物股票价格,圣诺生物股票交易,圣诺生物股票购买,圣诺生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"圣诺生物(688117)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供圣诺生物(688117)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}